Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Spyre TherapeuticsSYRE | Open-market sale | 06/25 | 06/26 | 15,000 sh2 trades | $87.13avg. | $1,307,000 | −13.3% | |
Peter Evan HarwinDirector | Spyre TherapeuticsSYRE | Open-market sale | 06/23 | 06/23 | 4,684,781 sh | $85.31 | $399,658,667.11 | −100.0% |
Fairmount Healthcare Fund IIDirector | Spyre TherapeuticsSYRE | Open-market sale | 06/23 | 06/23 | 4,684,781 sh | $85.31 | $399,658,667.11 | −100.0% |
Fairmount Funds ManagementDirector | Spyre TherapeuticsSYRE | Open-market sale | 06/23 | 06/23 | 4,684,781 sh | $85.31 | $399,658,667.11 | −100.0% |
Tomas KiselakDirector | Spyre TherapeuticsSYRE | Open-market sale | 06/23 | 06/23 | 4,684,781 sh | $85.31 | $399,658,667.11 | −100.0% |
Henderson Michael ThomasDirector | Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 06/22 | 06/23 | 20,000 sh | $100.00 | $2,000,000 | −22.6% |
Sheldon SloanChief Medical Officer | Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 06/03 | 06/03 | 8,333 sh | $75.00 | $624,975 | −100.0% |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 06/01 | 06/03 | 15,000 sh3 trades | $70.43avg. | $1,056,486.02 | −2.4% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 06/01 | 06/03 | 7,500 sh3 trades | $71.06avg. | $532,936.98 | −7.1% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 05/08 | 05/08 | 80,000 sh4 trades | $74.40avg. | $5,952,050.43 | −47.4% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 05/01 | 05/01 | 15,000 sh6 trades | $71.37avg. | $1,070,507 | −2.4% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 05/01 | 05/01 | 12,500 sh | $71.37 | $892,125 | −11.3% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 05/01 | 05/01 | 78,333 sh7 trades | $71.50avg. | $5,600,701.16 | −100.0% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 04/01 | 04/03 | 15,000 sh2 trades | $49.33avg. | $739,912.32 | −2.3% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 04/01 | 04/03 | 7,500 sh2 trades | $49.34avg. | $370,076 | −7.1% | |
Sheldon SloanChief Medical Officer | Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 04/01 | 04/03 | 7,958 sh | $50.00 | $397,900 | −100.0% |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 03/03 | 03/03 | 2,500 sh2 trades | $40.65avg. | $101,620 | −2.5% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 03/02 | 03/03 | 15,000 sh2 trades | $42.19avg. | $632,866 | −2.3% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 02/02 | 02/04 | 15,000 sh2 trades | $32.80avg. | $492,045.15 | −2.2% | |
Spyre TherapeuticsSYRE | Open-market sale10b5-1 plan | 01/02 | 01/06 | 15,000 sh3 trades | $30.68avg. | $460,134.12 | −2.2% |